In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tallying Late-Stage Licensing Opportunities

Executive Summary

At Windhover's Pharmaceutical Strategic Alliances conference in New York last month, 65% of the audience said by electronic poll that their firms were likely to seek to in-license a late-phase product candidate in the next year. But that's going to be easier said than done. There simply aren't many compounds available for licensing in the US.
Advertisement

Related Content

In Context: Aventis-Genta after Bristol-ImClone

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel